Day: April 2, 2024

Avicanna Reports Full Year 2023 Audited Financial Results

Written by Customer Service on April 2, 2024. Posted in Earnings Releases And Operating Results.

$16.8M in Revenue, representing an increase of 314% from 2022$6.7M Consolidated gross Profit, representing an increase of 500% from 2022 TORONTO, April 02, 2024 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce year end 2023 results and audited financial statements.2023 FINANCIAL HIGHLIGHTSRevenue growth of 314%, from $4 million in 2022 to $16.8 million in 2023, largely driven by the acquisition of Medical Cannabis by Shoppers from Shoppers Drug Mart and the launch of MyMedi.ca. Substantial revenue growth was achieved with a 19% increase in operational expenses. North American gross margins improvement of 28%, to reach...

Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

Written by Customer Service on April 2, 2024. Posted in Earnings Releases And Operating Results.

MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results. Fourth Quarter 2023 Highlights Clinical Updates Announced Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease (PD) On December 5, 2023, the Company announced the last patient last visit for its PD Phase III study of buntanetap and reported a substantial level of participation with patients enrolled at record pace. Out of 616 total patients screened, 523 were enrolled and 471 completed the trial across 67 sites (43 in the United States and 24 in the European Union). The Company confirmed...

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Written by Customer Service on April 2, 2024. Posted in Earnings Releases And Operating Results.

Year marked by growing body of promising data demonstrating Ampligen’s potential to address multiple high-value indications Company to host conference call and webcast today, April 2nd at 8:30 AM ET OCALA, Fla., April 02, 2024 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the full year 2023 and provided a business update. As previously announced, the Company will host a conference call and webcast today, Tuesday, April 2, 2024, at 8:30 AM ET (details below). “AIM reported positive data across many fronts in 2023 and the first quarter of 2024. We intend to build on this momentum throughout the year, as we focus on the execution of our operational, clinical and regulatory initiatives. My goal is to create stockholder value in the near- and long-term...

Eightco announces Full-Year 2023 Financial Results

Written by Customer Service on April 2, 2024. Posted in Public Companies.

2023 revenues of $75.3 million up 137% year-over-year from $31.8 million, driven by cell phone sales, beating guidance of $73.0 million 2023 SG&A excluding Depreciation & Amortization of $5.2 million, down 45% as a result of elimination of costs related to historical business effortsEaston, PA, April 02, 2024 (GLOBE NEWSWIRE) — Eightco Holdings Inc. (NASDAQ: OCTO) (the “Company” or “Eightco”), who’s subsidiaries provide inventory capital for e-commerce sellers as well as manufacturing solutions for product and packaging needs, today announced financial results for the fiscal year ended December 31, 2023. Paul Vassilakos, CEO of Eightco and President of Forever 8 Fund, LLC (“Forever 8”), the Company’s largest subsidiary, said “Our full-year consolidated revenue improvement was driven by revenue growth in our cell phone...

COMSTOCK RESOURCES, INC. ANNOUNCES PRIVATE OFFERING OF 6.75% SENIOR NOTES DUE IN 2029

Written by Customer Service on April 2, 2024. Posted in Public Companies.

FRISCO, TX, April 02, 2024 (GLOBE NEWSWIRE) — Comstock Resources, Inc. (“Comstock” or the “Company”) (NYSE: CRK) announced today that, subject to market conditions, it intends to offer $375.0 million principal amount of its 6.75% senior notes due in 2029 (the “New Notes”) in a private placement to eligible purchasers. The New Notes are a mirror issue to the Company’s existing 6.75% senior notes due 2029 (the “Original Notes”), of which $1,223.9 million aggregate principal amount is currently outstanding. The New Notes will have substantially identical terms as the Original Notes; however, the New Notes will be issued under a separate indenture and have a different CUSIP number from the Original Notes. Comstock intends to use the net proceeds from this offering to repay a portion of the borrowings currently...

Erdene Announces Year-End Results and Provides Bayan Khundii Project Update

Written by Customer Service on April 2, 2024. Posted in Public Companies.

HALIFAX, Nova Scotia, April 02, 2024 (GLOBE NEWSWIRE) — Erdene Resource Development Corp. (TSX:ERD; MSE:ERDN) (“Erdene” or the “Company”) is pleased to announce operating and financial results for the year ended December 31, 2023, and to provide an update on progress at its Bayan Khundii Gold Project (“BK” or “Project”). This release should be read in conjunction with the Company’s 2023 Financial Statements and MD&A, available on the Company’s website and SEDAR+. Peter Akerley, Erdene’s President and CEO stated, “The past year was a transformative period for Erdene with the striking of our Strategic Alliance with Mongolian Mining Corporation (“MMC”), Mongolia’s leading publicly traded mining company, the commencement of construction at the Bayan Khundii gold project and continued exploration success...

SLB Announces Agreement to Acquire ChampionX in an All-Stock Transaction

Written by Customer Service on April 2, 2024. Posted in Public Companies.

Acquisition strengthens SLB as a leader in production space, with world-class production chemicals and artificial lift technologies Combined portfolios will drive customer value through deep industry expertise and digital integration, as well as enhanced equipment life and production optimization ChampionX shareholders to receive 0.735 SLB shares for each share of ChampionX Annual pre-tax synergies to reach approximately $400 million within three years SLB will increase its total returns to shareholders to a target of $3 billion in 2024; sets target for returns to shareholders of $4 billion in 2025HOUSTON, April 02, 2024 (GLOBE NEWSWIRE) — SLB (NYSE: SLB) and ChampionX Corporation (NASDAQ: CHX) today announced a definitive agreement for SLB to purchase ChampionX in an all-stock transaction. The agreement was unanimously approved...

Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Written by Customer Service on April 2, 2024. Posted in Public Companies.

TORONTO, April 02, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver. The three new hospitals joining the Phase II study are Istanbul University-Cerrahpaşa, Sütçü İmam University Hospital in the city of Kahramanmaraş, and the Gazi University Hospital in Ankara, the capital of Turkey. The trial now has a total of seven clinical sites across Turkey and Canada. About the Phase II trial for LSALT Peptide targeting CS-AKI Arch Biopartners...

Coda Octopus Group Reports that its Echoscope® Technology used as the Primary Survey Tool in the Francis Scott Key Bridge ongoing salvage operations.

Written by Customer Service on April 2, 2024. Posted in Public Companies.

ORLANDO, FL, April 02, 2024 (GLOBE NEWSWIRE) — Coda Octopus Group, Inc. (“CODA” or the “Company”) (Nasdaq: CODA), a global market leader in 3D/4D/5D/6D imaging sonar technology for real time subsea intelligence and cutting-edge diving technology, today reported that its Echoscope® technology is being used on the ongoing salvage operations. The news highlighting this can be found here. Commenting on this, Blair Cunningham, CODA’s President of Technology, stated “we are humbled and pleased that Coda Octopus and its technology can play a part as the primary survey tool in these ongoing operations, and I am pleased that I can be onsite assisting in the ongoing operations. As noted by SUPSALV in the article referred to above, the conditions are challenging and compounded by poor visibility water conditions …the Echoscope® “is the...

FTAI Aviation Commences Cash Tender Offer for Any and All of Its Outstanding 6.50% Senior Notes Due 2025

Written by Customer Service on April 2, 2024. Posted in Public Companies.

NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) — FTAI Aviation Ltd. (NASDAQ: FTAI), a Cayman Islands exempted company (the “Company” or “FTAI”) is announcing today that Fortress Transportation and Infrastructure Investors LLC (“FTAI LLC”), a wholly owned subsidiary of the Company, has commenced an offer (the “Tender Offer”) to purchase for cash any and all of the $650.0 million outstanding principal amount of its 6.50% Senior Notes due 2025 (the “2025 Senior Notes”) on the terms and conditions described in FTAI LLC’s Offer to Purchase, dated April 2, 2024 (the “Offer to Purchase”). Capitalized terms used but not defined in this announcement have the meanings given to them in the Offer to Purchase. The following table sets forth certain terms of the Tender Offer:Series of Notes CUSIP Number Aggregate Principal Amount Outstanding Tender...

Day: April 2, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice